Unknown

Dataset Information

0

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.


ABSTRACT: BACKGROUND:The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. METHODS:Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored. Ombrabulin was escalated from 11.5 to 42?mg?m(-2) with 75?mg?m(-2) docetaxel, then from 30 to 35?mg?m(-2) with 100?mg?m(-2) docetaxel. Recommended phase II dose cohorts were expanded. RESULTS:Fifty-eight patients were treated. Recommended phase II doses were 35?mg?m(-2) ombrabulin with 75?mg?m(-2) docetaxel (35/75?mg?m(-2); 13 patients) and 30?mg?m(-2) ombrabulin with 100?mg?m(-2) docetaxel (30/100?mg?m(-2); 16 patients). Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100). Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anaemia were common, as were neutropaenia and leukopaenia. Diarrhoea, nail disorders and neurological symptoms were frequent at 100?mg?m(-2) docetaxel. Pharmacokinetic analyses did not show any relevant drug interactions. Ten patients had partial responses (seven at 30?mg?m(-2) ombrabulin), eight lasting >3 months. CONCLUSIONS:Sequential administration of ombrabulin with 75 or 100?mg?m(-2) docetaxel every 3 weeks is feasible.

SUBMITTER: Eskens FA 

PROVIDER: S-EPMC4007230 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Eskens F A L M FA   Tresca P P   Tosi D D   Van Doorn L L   Fontaine H H   Van der Gaast A A   Veyrat-Follet C C   Oprea C C   Hospitel M M   Dieras V V  

British journal of cancer 20140408 9


<h4>Background</h4>The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours.<h4>Methods</h4>Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored. Ombrabulin was escalated from 11.5 to 42 mg m(-2) with 75 mg m(-2) docetaxel, then from 30 to 35 mg m(-2) with 100 mg m(-2) docetaxel. Recommended phase II dose cohorts were expanded  ...[more]

Similar Datasets

| S-EPMC4720091 | biostudies-literature
| S-EPMC7066534 | biostudies-literature
| S-EPMC3494424 | biostudies-literature
| S-EPMC3778312 | biostudies-literature
| S-EPMC3419955 | biostudies-literature
| S-EPMC5931096 | biostudies-other
| S-EPMC3495895 | biostudies-literature
| S-EPMC3048208 | biostudies-other
| S-EPMC8018321 | biostudies-literature
| S-EPMC6735221 | biostudies-literature